Centric Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Centric Wealth Management's VRTX Position: Q3 2026 in Review
Centric Wealth Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 403 shares worth $222K. The stake represents 0.03% of the portfolio and ranks #208 among its holdings. This is a return to the name: Centric Wealth Management previously reported a position in VRTX as recently as Q3 2022.
Centric Wealth Management first reported a position in VRTX in Q3 2022 and has held it in 2 quarters since. The position peaked at $256K in Q3 2022. 1,775 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Centric Wealth Management held 403 shares of Vertex Pharmaceuticals worth $222K as of Q3 2026.
- Vertex Pharmaceuticals was a new Centric Wealth Management position in Q3 2026.
- Vertex Pharmaceuticals made up 0.03% of Centric Wealth Management's portfolio in Q3 2026, its #208 holding.
- Centric Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 2 quarters since.
- Centric Wealth Management's Vertex Pharmaceuticals position peaked at $256K in Q3 2022.
- 1,775 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Centric Wealth Management's 13F filing for Q3 2026, filed 12 Nov 2026.